Mankind Pharma Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Mankind Pharma Q2 results FY27 announcement is the next scheduled earnings event for Mankind Pharma Ltd., Mankind Pharma is one of India's largest pharmaceutical companies, manufacturing and marketing a broad range of prescription medicines and consumer healthcare products domestically.. The stock traded at Rs 2,250.00 on the NSE on 17 September 2026, up 0.18% from the previous close of Rs 2,246.00, about 15.9% below its 52-week high of Rs 2,674.00 and 17.8% above its 52-week low of Rs 1,909.70.

What makes the Mankind Pharma Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 3,697.00 crore of revenue and a profit of Rs 520.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 4,031.00 crore and a profit of Rs 574.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Mankind Pharma Q2 Results FY27 Date?

The Mankind Pharma Q2 results date for FY27 is not confirmed. As of 17 September 2026, Mankind Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Mankind Pharma Q2 results date becomes public through that filing rather than through any advance announcement.

Also read – Jindal Steel and Power Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Mankind Pharma Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Mankind Pharma.

Mankind Pharma Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Mankind Pharma Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Mankind Pharma. The Mankind Pharma Q2 results watchlist below is built from what the company has actually reported and disclosed.

Mankind Pharma Q2 results for the September 2026 quarter arrive against a backdrop of steady, consistent performance over the last five quarters. Revenue has grown from 3,570 crore to 4,031 crore across that stretch, while operating margin has stayed in a tight 24% to 27% band throughout. That consistency sets a relatively stable base of comparison heading into the Mankind Pharma Q2 results for the September 2026 quarter.

Mankind Pharma's scale across chronic and acute therapy segments, along with its consumer healthcare portfolio, has supported this steady revenue climb without any loss-making quarter in the recent record. Operating profit has risen broadly in line with revenue, pointing to margins that have not come under meaningful pressure even as the topline has expanded. One quarter in the recent run, December 2025, saw net profit dip versus the operating profit trend because of an unusually negative other income figure, a one-off item rather than a sign of core business weakness heading into the Mankind Pharma Q2 results.

Heading into the Mankind Pharma Q2 results for the September 2026 quarter, the core operating trends, revenue growth and stable operating margin, remain the more relevant markers than any single other-income swing. Return on equity near 13% and a low dividend payout suggest a company still reinvesting for growth. Performance in the September 2026 quarter will likely be judged on whether this multi-quarter consistency in margins continues.

Check Mankind Pharma Ltd. Live Fundamentals on the Univest Screener

Mankind Pharma Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Mankind Pharma Ltd. reported revenue of Rs 4,031.00 crore in Q1 FY27, up 12.91% from Rs 3,570.00 crore in Q1 FY26, and a profit of Rs 574.00 crore at the net level, up 28.99% from Rs 445.00 crore in Q1 FY26. These are reported actuals, not estimates.

Also read – JK Cement Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Sequentially, revenue was up 17.08% over the March 2026 quarter figure of Rs 3,443.00 crore, and net profit was up 2.68% from Rs 559.00 crore in Q4 FY26. Operating margin stood at 24.0% in Q1 FY27 against 25.0% in the September 2025 quarter, which is the comparison the Mankind Pharma Q2 results print will be read against.

Q2 FY26 Base: The Comparison Mankind Pharma Q2 Results FY27 Must Beat

Mankind Pharma Ltd. reported revenue of Rs 3,697.00 crore and a profit of Rs 520.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Mankind Pharma Q2 results preview.

Net profit in that base quarter was below the Rs 574.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 3,697.00 crore sits below the Rs 4,031.00 crore of the June 2026 quarter, which frames how much sequential movement the Mankind Pharma Q2 results print needs to show growth.

Mankind Pharma Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	3,697.00	520.00
Q3 FY26 (Dec 2025)	3,567.00	414.00
Q4 FY26 (Mar 2026)	3,443.00	559.00
Q1 FY27 (Jun 2026)	4,031.00	574.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Mankind Pharma Q2 results preview uses.

Revenue across those four quarters ranged from Rs 3,443.00 crore to Rs 4,031.00 crore, and net profit from Rs 414.00 crore to Rs 574.00 crore. That spread is the honest context for the Mankind Pharma Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Mankind Pharma Q2 Results FY27

The Mankind Pharma Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Mankind Pharma has already reported.

Consistent Revenue Growth

Mankind Pharma has posted rising revenue in four of the last five quarters, moving from 3,570 crore to 4,031 crore, without any quarter of contraction beyond a modest dip in March 2026. This steadiness reflects the breadth of the company's therapy portfolio and its consumer healthcare business. Ahead of the Mankind Pharma Q2 results, this growth trajectory forms the primary reference point.

Stable Operating Margins

Ahead of the Mankind Pharma Q2 results, operating margin has stayed within a narrow 24% to 27% range across the last five quarters, among the more stable margin profiles for a large pharma company of this size. This stability suggests limited raw material or pricing pressure has flowed through to the operating line so far. Whether this band holds in the Mankind Pharma Q2 results will be a key watch point.

The December 2025 Other Income One-Off

Net profit in December 2025 came in below what the operating profit trend would have suggested, largely because other income swung to a negative 31 crore that quarter versus a positive 49 to 94 crore range in the surrounding quarters. This appears to be a one-off item rather than a recurring feature of the business, and it did not affect the underlying operating profit or revenue trend. Investors reviewing the Mankind Pharma Q2 results are likely to look through this isolated item toward the more consistent operating trend.

Mankind Pharma Q2 Results FY27: Share Price and Valuation Going Into the Print

Mankind Pharma share price today is Rs 2,250.00 on the NSE, up Rs 4.00 or 0.18% from the previous close of Rs 2,246.00 on 17 September 2026, ahead of the Mankind Pharma Q2 results announcement.

Metric	Value (17 September 2026)
NSE Symbol	MANKIND
Current Market Price	Rs 2,250.00
52-Week High	Rs 2,674.00
52-Week Low	Rs 1,909.70
Market Capitalisation	Rs 92605 crore
PE Ratio	43.48
PB Ratio	5.70
EPS (TTM)	Rs 51.75
Book Value per Share	Rs 395.00
Debt to Equity	0.39
Return on Equity	13.1%
50-Day Moving Average	Rs 2429.96
200-Day Moving Average	Rs 2280.68
RSI (14)	29.16

The stock trades below both its 50-day average of Rs 2429.96 and its 200-day average of Rs 2280.68, with a 14-day RSI of 29.16. None of this is a view on where the shares go once the Mankind Pharma Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Mankind Pharma Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Mankind Pharma Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Mankind Pharma Q2 results print in proportion.

1. Revenue against the Rs 3,697.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 520.00 crore in that same quarter
3. Operating margin against 24.0% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Mankind Pharma Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Mankind Pharma Q2 Results FY27

The Mankind Pharma Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Mankind Pharma Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Mankind Pharma Q2 results FY27 print faces a base of Rs 3,697.00 crore in revenue and a profit of Rs 520.00 crore, with the most recent quarter having delivered Rs 4,031.00 crore and a profit of Rs 574.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Mankind Pharma, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Mankind Pharma Q2 Results FY27

What is the Mankind Pharma Q2 results date for FY27?

Ans. The Mankind Pharma Q2 results date for FY27 is not confirmed. Mankind Pharma Ltd. had not filed a board meeting intimation with the NSE or BSE as of 17 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Mankind Pharma Q2 results 2026 cover?

Ans. The Mankind Pharma Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Mankind Pharma Ltd. reports revenue, operating profit and net profit for that period, and the Mankind Pharma Q2 results filing also carries the notes to the accounts.

What were the Mankind Pharma Q1 FY27 results?

Ans. Mankind Pharma Ltd. reported revenue of Rs 4,031.00 crore in Q1 FY27 and a profit of Rs 574.00 crore at the net level. Revenue was up 12.91% versus Q1 FY26 and net profit was up 28.99% from Rs 445.00 crore in Q1 FY26.

What were Mankind Pharma Q2 FY26 results in the September 2025 quarter?

Ans. Mankind Pharma Ltd. reported revenue of Rs 3,697.00 crore and a profit of Rs 520.00 crore in Q2 FY26. Operating margin was 25.0%. Those figures form the base for the Mankind Pharma Q2 results FY27 comparison.

What are the main Mankind Pharma Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Mankind Pharma Q2 results expectations centre on revenue against the Rs 3,697.00 crore base, net profit against a profit of Rs 520.00 crore, operating margin against 24.0% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Mankind Pharma share price today ahead of the Q2 earnings?

Ans. Mankind Pharma share price is Rs 2,250.00 on the NSE as of 17 September 2026, up 0.18% from Rs 2,246.00. The stock is about 15.9% below its 52-week high of Rs 2,674.00 and 17.8% above its 52-week low of Rs 1,909.70, at a market capitalisation of Rs 92605 crore.

Is Mankind Pharma a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Mankind Pharma Ltd. The stock trades at a price-to-book ratio of 5.70 with a return on equity of 13.1%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.